AGN 193836

Drug Profile

AGN 193836

Latest Information Update: 02 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class Antineoplastics; Retinoids
  • Mechanism of Action Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 09 Sep 1999 Profile reviewed but no significant changes made
  • 11 Mar 1997 New profile
  • 11 Mar 1997 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top